Recognition of non-operating expenses (derivative valuation loss)
TOWA PHARMACEUTICAL CO.,LTD. (reporting company)
Derivative Transactions
The exchange rate moved in favor of the yen compared with the end of the fiscal year ended March 2026, and the long-term interest rate differential between Japan and the United States widened.
¥2,355 million (non-operating expense)
Second quarter (interim period) of the fiscal year ending March 2027, consolidated accounting period (1 April 2026 to 30 September 2026)
The consolidated earnings forecast for the fiscal year ending March 2027, announced on 14 May 2026, has not been revised. Because the outlook for foreign exchange rates remains uncertain, gains and losses on derivative valuations have not been included in the consolidated earnings forecast. The company will promptly disclose any revision if one becomes necessary.
The outlook for foreign exchange rates remains uncertain, and gains and losses on derivative valuations have not been included in the consolidated earnings forecast. The company will promptly disclose any revision if one becomes necessary.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating expenses (derivative valuation loss) |
| Subject Entity | TOWA PHARMACEUTICAL CO.,LTD. (reporting company) |
| Target Locations / Products | Derivative Transactions |
| Cause | The exchange rate moved in favor of the yen compared with the end of the fiscal year ended March 2026, and the long-term interest rate differential between Japan and the United States widened. |
| Amount of Impact on Business Performance | ¥2,355 million (non-operating expense) |
| Accounting period in which recognized | Second quarter (interim period) of the fiscal year ending March 2027, consolidated accounting period (1 April 2026 to 30 September 2026) |
| Impact on Earnings Forecast | The consolidated earnings forecast for the fiscal year ending March 2027, announced on 14 May 2026, has not been revised. Because the outlook for foreign exchange rates remains uncertain, gains and losses on derivative valuations have not been included in the consolidated earnings forecast. The company will promptly disclose any revision if one becomes necessary. |
| Outlook | The outlook for foreign exchange rates remains uncertain, and gains and losses on derivative valuations have not been included in the consolidated earnings forecast. The company will promptly disclose any revision if one becomes necessary. |
| Planned follow-up disclosure | The company will promptly disclose any revision if one becomes necessary. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The exchange rate moved in favor of the yen compared with the end of the fiscal year ended March 2026, and the long-term interest rate differential between Japan and the United States widened.